MedTrace Logo

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

NCT03565861 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-03-13

No results posted yet for this study

Summary

This study assesses the safety, tolerability and pharmacokinetics of NP10679 when delivered intravenously in escalating dose levels in comparison to placebo.

Conditions

  • Safety Issues

Interventions

DRUG

Placebo

Intravenous vehicle

DRUG

NP10679

NP10679

Sponsors & Collaborators

  • Neurop Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Zaczek, Ph.D. · Neurop Inc.

  • Paolo DePetrillo · Pharmaron CPC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-06
Primary Completion
2018-09-02
Completion
2018-10-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03565861 on ClinicalTrials.gov